DaVita Inc
XBER:TRL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
DaVita Inc
XBER:TRL
|
US |
|
C
|
Credit Suisse Group AG
XBER:CSX
|
CH |
|
Citius Pharmaceuticals Inc
F:47N
|
US |
|
N
|
New Oriental Education & Technology Group Inc
BMV:EDUN
|
CN |
|
F
|
First Majestic Silver Corp
XMUN:FMV
|
CA |
|
S
|
Sabra Health Care REIT Inc
SWB:SBC
|
US |
|
C
|
Celestica Inc
XMUN:CTW
|
CA |
|
D
|
Dominion Energy Inc
XBER:DOD
|
US |
|
W
|
Wendys Co
XMUN:TQK
|
US |
|
D
|
Dechra Pharmaceuticals PLC
F:1PK
|
UK |
Wall St Price Targets
TRL Price Targets Summary
DaVita Inc
According to Wall Street analysts, the average 1-year price target for TRL is 74.53 EUR with a low forecast of 61.37 EUR and a high forecast of 96.21 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is TRL's stock price target?
Price Target
74.53
EUR
According to Wall Street analysts, the average 1-year price target for TRL is 74.53 EUR with a low forecast of 61.37 EUR and a high forecast of 96.21 EUR.
What is the Revenue forecast for DaVita Inc?
Projected CAGR
5%
Over the last 14 years, the compound annual growth rate for Revenue has been 5%. The projected CAGR for the next 8 years is 5%.
What is the Operating Income forecast for DaVita Inc?
Projected CAGR
6%
Over the last 14 years, the compound annual growth rate for Operating Income has been 4%. The projected CAGR for the next 8 years is 6%.
What is the Net Income forecast for DaVita Inc?
Projected CAGR
17%
Over the last 14 years, the compound annual growth rate for Net Income has been 3%. The projected CAGR for the next 8 years is 17%.
